Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
"Compounding pharmacies are making their own versions of blockbuster weight loss drugs"
Quick Comparison: Eloralintide vs Retatrutide Attribute Eloralintide Retatrutide Developer Eli Lilly Eli Lilly Class Selective amylin receptor agonist (LY-3841136 class) Triple agonist (LY3437943) Receptors targeted Amylin receptor only GIP + GLP-1 + glucagon Administration in trials Once weekly Once weekly, subcutaneous Phase 2 population 263 adults with obesity or overweight plus at least one obesity-related comorbidity, without type 2 diabetes 338 participants with obesity or overweight with weight-related conditions, excluding type 2 diabetes Phase 2 duration 48 weeks 48 weeks Reported mean weight reduction 9.5%-20.1% across arms vs 0.4% placebo (~20.1% at 9 mg) Up to 24.2% (~26.2 kg / ~58 lb) at the highest dose Tolerability signal Mild-to-moderate GI events
After exposing the right knee femoral condyle with a medial para-patellar incision, cartilage was removed using a surgical blade from the trochlear surface
The review also highlights the success of these synthetic medications in treating comorbidities
US$ 24.39
US$ 23.81
US$ 29.95
US$ 20.61
US$ 21.44
US$ 23.59
US$ 22.22
